Table 6.
Summary of reported miRNAs and their targets in angiogenesis.
| miRNAs | Targets | Effector cells | Signal pathways | References |
|---|---|---|---|---|
| Proangiogenesis | ||||
| miR-126 | Spred-1 | HEPCs | VEGF | |
| PIK3R2 | HEPCs | VEGF | [156, 157] | |
| CCN1 | HEPCs | TEN/AKT | ||
|
| ||||
| miR-130a | GAX | HUVECs and EGM-2 | Transcription | |
| HOXA5 | HUVECs and EGM-2 | Transcription | [158, 159] | |
| PTEN | MI mouse | PI3K/Akt | ||
|
| ||||
| miR-17–92 cluster | Tsp1 | HUVECs | VEGF | |
| CTGF | HUVECs | TGFβ | [160] | |
| BMP4 | HUVECs | Bmp4/Smad | ||
|
| ||||
| miR-210 | Ephrin-A3, | HUVECs | VEGF | [81, 161, 162] |
| PTP1b | MHL-1Cs | VEGF | ||
|
| ||||
| miR-146a | VEGF | hMSCs | Shh | [65] |
|
| ||||
| miR-296 | HGS | HBMVECs | [163] | |
|
| ||||
| miR-378 | SuFu | U87 cells | Shh | [164, 165] |
| Fus-1 | U87 cells | Shh | ||
|
| ||||
| miR-132 | p120RasGAP | HUVECs | Ras | [166] |
|
| ||||
| miR-23/27 | Sprouty2, | HUVECs | ERK-MAPK | [167] |
| Sema6A | HUVECs | VECF | ||
|
| ||||
| miR-27b | Dll4, | LLC1 and ATCC | Dll4/Notch | [168] |
| PPARγ | LLC1 and ATCC | PPAR | ||
|
| ||||
| miR-24 | GATA2, | HVSMCs and HUVECs | cGMP-PKG | [169, 170] |
| PAK4 | HVSMCs and HUVECs | TGF-β1/Smads | ||
| eNOS | MI mouse, HUVECs and HMVECs | PI3K/Akt | ||
|
| ||||
| Antiangiogenesis | ||||
| miR-214 | XBP1 | HUVECs | VEGF | [171] |
|
| ||||
| miR-34 family | SIRT1 | HUVECs, HMVECs and HAECs | AMPK | [172–174] |
| vinculin | LNA-antimiR-34–treated MI mice and H9c2 cell | FAK1 | ||
| Pofut1 | LNA-antimiR-34–treated MI mice and H9c2 cell | Notch | ||
| Notch1 | LNA-antimiR-34–treated MI mice and H9c2 cell | Notch | ||
| VEGF | LNA-antimiR-34–treated MI mice and H9c2 cell | VEGF | ||
| Sema4b | LNA-antimiR-34–treated MI mice and H9c2 cell | VECF | ||
|
| ||||
| miR-29a/101a | TGFb-1 | MI rats | TGFb pathway | [175] |
|
| ||||
| miR-15b-5p | AKT3 | HUVECs | PI3K-Akt | [176] |
|
| ||||
| miR-100 | mTOR | ESMCs, VSMCs | mTOR | [177] |
|
| ||||
| miR-200b | ZEB1/SIP1 | MDCKCs and HBCCs | mTOR | [178–181] |
| GATA2 | Dermal wound-edge ECs | VEGF | ||
| VEGFR2 | Dermal wound-edge ECs | VEGF | ||
| Flt1 | HUVECs | VEGF | ||
| KDR | HUVECs | VEGF | ||
|
| ||||
| miR-503 | cdc25A | HUVECs, HMVECs and HVSMCs | MAPK | [182] |
| CCNE1 | HUVECs, HMVECs and HVSMCs | Notch | ||
|
| ||||
| miR-15a | FGF2 | HUVECs | PI3K-AKT | [183, 184] |
| VEGF | HUVECs | VEGF | ||
|
| ||||
| miR-320 | IGF-1 | MCECs, NRCMs | PI3K-Akt | [185, 186] |
| Hsp20 | MCECs, NRCMs | RNA degradation | ||
| Ets2 | MCECs, NRCMs | PI3K-Akt | ||
|
| ||||
| miR-329 | CD146 | HUVECs, HMECs | VEGF and TNF-α | [187] |
|
| ||||
| miR-92a | ITGA5 | RMUG-S, OVISE and RMG-1 | Rho/ROCK | [188–190] |
CCNE1: cyclin E1; cdc25A: cell division cycle 25A; CTGF: connective tissue growth factor; Dll4: delta-like protein 4; eNOS: endothelial nitric oxide synthase; Ets2: Euro Truck Simulator 2; FGF2: fibroblast growth factor 2; FGFR1: fibroblast growth factor receptor 1; GATA2: GATA binding protein 2; GAX: gaseous oxygen; HGS: hepatocyte growth factor-regulated tyrosine kinase substrate; HOXA5: homeobox A5; IGF-1: insulin-like growth factor 1; ITGA5: integrin subunits a5; mTOR: mechanistic target of rapamycin; PIK3R2: phosphoinositol-3 kinase regulatory subunit 2; Pofut1: protein O-fucosyltransferase 1; Pparγ: peroxisome proliferator-activated receptor γ; PTEN: phosphatase and tensin homolog; Sema4b: semaphorin 4B; Sema6A: semaphorin 6A; SIP1: Smad interacting protein 1; SIRT1: Sirtuin 1; Sprouty2: sprouty homolog 2; Tsp1: thrombospondin-1; VEGF: vascular endothelial growth factor; VEGFR2: vascular endothelial growth factor receptor 1; XBP1: X-box binding protein 1; ZEB1: zinc finger E-box-binding homeobox 1; FAK: focal adhesion kinase; HUVECs: human umbilical vein ECs; EGM-2: endothelial growth medium 2; MHL-1Cs: mouse HL-1 cardiomyocytes; hMSCs: human mesenchymal stem cells; Shh: sonic hedgehog signaling; HBMVECs: human brain microvascular endothelial cells; LLC1: Lewis lung carcinoma; ATCC: RAW 264.7 mouse macrophage cell lines; HVSMCs: human vascular smooth muscle cells; HUVECs: human umbilical vein endothelial cells; HMVECs: human microvascular ECs; HAECs: human aortic endothelial cell; ESMCs: endothelial smooth muscle cells; VSMCs: vascular smooth muscle cells; HVSMCs: human VSMCs cells; MDCKCs: Madin-Darby canine kidney cells; HBCCs: human breast cancer cells; dermal wound-edge ECs: dermal wound-edge endothelial cells; MCECs: mouse cardiac endothelial cells; NRCMs: neonatal rat cardiomyocytes; HMECs: human microvascular endothelial cells.